A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome ...

The randomised trial saw over half of patients dosed with Sunosi were able to achieve clinical response to the therapy ...

Solriamfetol achieved the primary and key secondary endpoint of the Phase III FOCUS trial by significantly lowering attention ...

Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the ...

In Axsome's study of 516 adults with ADHD, the 150-milligram dose of solriamfetol helped ease symptoms by 45% after six weeks of treatment, compared to a placebo. Solriamfetol, branded as Sunosi ...

(PLOS One) Dopamine and norepinephrine reuptake inhibitor solriamfetol (Sunosi), approved for excessive daytime sleepiness, significantly improved attention deficit-hyperactivity disorder (ADHD ...

which evaluated solriamfetol for the treatment of attention deficit hyperactivity disorder (ADHD), has met its primary and key secondary endpoints. Axsome currently markets solriamfetol as Sunosi ...

Axsome is evaluating Sunosi in separate phase III studies for treating attention deficit hyperactivity disorder (ADHD), major depressive disorder (MDD), binge eating disorder and excessive ...

Axsome Therapeutics’ Phase III Focus trial investigating its attention-deficit hyperactivity disorder (ADHD) therapy, Sunosi (solriamfetol), has met its primary endpoint and provided a ...